
|Articles|June 11, 2015
- Precision Medicine
- Volume 2
- Issue 1
Clinical Validation and Utility of a Liquid Biopsy in NSCLC
Author(s)Veena Singh, MD
Veena Singh, MD, senior vice president and senior medical director, Biocept, Inc., discusses the clinical validation and utility of a liquid biopsy in non-small cell lung cancer (NSCLC) using circulating tumor cells (CTCs) and ctDNA to analyze EGFR, ALK and ROS status.
Advertisement
Veena Singh, MD, senior vice president and senior medical director, Biocept, Inc., discusses the clinical validation and utility of a liquid biopsy in non-small cell lung cancer (NSCLC) using circulating tumor cells (CTCs) and ctDNA to analyze EGFR, ALK and ROS status.
<<<
Articles in this issue
about 11 years ago
Nivolumab and Future Biomarkers in NSCLCabout 11 years ago
Significance of the NCI Molecular Analysis for Therapy Choice Programabout 11 years ago
Scoring System May Help Guide Therapy in Triple-Negative Breast CancerAdvertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Long-Term OMNIVORE Data Show Durable Treatment-Free Survival in RCC
2
Phase 3 ENHANCE Trial: Magrolimab Adds Toxicity, Not Benefit, in MDS
3
On-Body Injector Technology Streamlines Subcutaneous Myeloma Therapy
4
De-Escalated Neoadjuvant HER2-Targeted Therapy Shows Durable 5-Year Survival
5






























